0.00
0.00%
Close of 5 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Memphasys
Its shares trade on ASX under the ticker MEM.AX. It has been listed since 14 May 2007. In the fiscal year to 30 June 2026, it reported revenue of A$273,793 and a net loss of A$4.1m. At that date it held total assets of A$11.2m and shareholders' equity of A$4.2m.
Memphasys Ltd. is a life sciences company. The company is headquartered in Homebush West, New South Wales. The company went IPO on 2007-05-14. The firm is engaged in developing novel medical devices, diagnostics, and media with applications to assisted reproduction technology (ART) in humans and animals. Its reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The firm's product pipeline includes Felix, ROSA, and AI-Port. The Felix is a patented, automated device for quickly separating high quality sperm from semen for use in human in vitro fertilization (IVF) procedures without causing damage to DNA. Felix has a sizable target market worldwide. The Company’s ROSA is an in vitro diagnostic that assesses semen and blood samples for the presence of oxidative stress. The AI-Port stores and transports animal semen for artificial insemination (AI) for up to four days without the harmful effects of freezing sperm used in standard AI procedures in livestock.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 14 May 2007
- Website
- memphasys.com ↗
Leadership
Pay as last reported
- Mr. Robert CookeNon-Executive Independent Chairman of the BoardA$18,205
- Ms. Lindley EdwardsNon-Executive Chairman of the Board
- Dr. David AliChief Executive Officer, Executive Director, since 2023
- Mr. Pablo NeyertzDirector of FinanceA$167,061
- Prof. John AitkenResearch DirectorA$281,374
- Assoc. Prof. Hassan BakosDirector of Operations
- Mr. Nick GorringOperations ManagerA$166,447
- Mr. Andrew MetcalfeCompany Secretary
- Mr. Michael AtkinsIndependent Non-Executive Director
- Mr. Paul WrightNon-Executive Independent DirectorA$50,019
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Memphasys Ltd. is a life sciences company headquartered in Homebush West, New South Wales.
- The company has a product pipeline including Felix, ROSA, and AI-Port.
- Felix is a patented automated device for sperm separation in IVF procedures.
Weaknesses
- The company's product pipeline includes only three products: Felix, ROSA, and AI-Port.
- The company's website is provided as https://www.memphasys.com/ but no additional details are given.
- The company's IPO date is 2007-05-14, indicating a long history without recent updates.
Opportunities
- Felix has a sizable target market worldwide for IVF procedures.
- ROS A assesses semen and blood samples for oxidative stress, offering diagnostic applications.
- AI-Port stores and transports animal semen for AI procedures without freezing, providing a unique solution.
Threats
- The company's product pipeline is limited to three products, which may limit growth potential.
- The company's website does not provide additional details beyond basic information.
- The company has been operating since 2007 without recent updates, suggesting possible stagnation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.